| Melissa Mcduffie Hamer, FNP-C | |
|
800 E Cheves St, Florence, SC 29506-2650 | |
| (843) 777-5646 | |
| (843) 777-5648 |
| Full Name | Melissa Mcduffie Hamer |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 6 Years |
| Location | 800 E Cheves St, Florence, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447717244 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 22613 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mcleod Regional Medical Center Of The Pee Dee, Inc | 7416851852 | 218 |
News Archive
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
AliveCor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company clearance for two new algorithms giving users instant feedback on their electrocardiogram (ECG) recordings and expanding its automated interpretation service offerings.
IRIS International, Inc. a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that Iris Molecular Diagnostics (IMD)has been granted Patent No. EP1842226B1 by the European Patent Office (EPO) covering aspects of IMD's NADiA ultra-sensitive protein detection and cell phenotyping platform, which can detect proteins in the femtogram (1 quadrillionth) per milliter range and phenotype single cells.
CSOS, China's first emergency assistance specialist with a global servicing capability and hospital network, announced today that it has been in full compliance with international emergency medical service (EMS) protocols as an initiative to promote best emergency care practices and medical excellence for government agencies, insurance companies, institutional clients and to the general public in China.
A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (INO), with or without the drug blinatumomab, is safe and effective in patients over 60 years of age who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative ALL.
› Verified 8 days ago
| Entity Name | Mcleod Regional Medical Center Of The Pee Dee, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154371433 PECOS PAC ID: 7416851852 Enrollment ID: O20031126000251 |
News Archive
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
AliveCor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company clearance for two new algorithms giving users instant feedback on their electrocardiogram (ECG) recordings and expanding its automated interpretation service offerings.
IRIS International, Inc. a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that Iris Molecular Diagnostics (IMD)has been granted Patent No. EP1842226B1 by the European Patent Office (EPO) covering aspects of IMD's NADiA ultra-sensitive protein detection and cell phenotyping platform, which can detect proteins in the femtogram (1 quadrillionth) per milliter range and phenotype single cells.
CSOS, China's first emergency assistance specialist with a global servicing capability and hospital network, announced today that it has been in full compliance with international emergency medical service (EMS) protocols as an initiative to promote best emergency care practices and medical excellence for government agencies, insurance companies, institutional clients and to the general public in China.
A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (INO), with or without the drug blinatumomab, is safe and effective in patients over 60 years of age who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative ALL.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Mcduffie Hamer, FNP-C 800 E Cheves St Ste 170, Florence, SC 29506-2651 Ph: (843) 777-5646 | Melissa Mcduffie Hamer, FNP-C 800 E Cheves St, Florence, SC 29506-2650 Ph: (843) 777-5646 |
News Archive
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
AliveCor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company clearance for two new algorithms giving users instant feedback on their electrocardiogram (ECG) recordings and expanding its automated interpretation service offerings.
IRIS International, Inc. a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that Iris Molecular Diagnostics (IMD)has been granted Patent No. EP1842226B1 by the European Patent Office (EPO) covering aspects of IMD's NADiA ultra-sensitive protein detection and cell phenotyping platform, which can detect proteins in the femtogram (1 quadrillionth) per milliter range and phenotype single cells.
CSOS, China's first emergency assistance specialist with a global servicing capability and hospital network, announced today that it has been in full compliance with international emergency medical service (EMS) protocols as an initiative to promote best emergency care practices and medical excellence for government agencies, insurance companies, institutional clients and to the general public in China.
A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (INO), with or without the drug blinatumomab, is safe and effective in patients over 60 years of age who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative ALL.
› Verified 8 days ago
Mrs. Callie Hanson Carpenter, F.N.P Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 555 E Cheves St, Florence, SC 29506 Phone: 843-777-2000 | |
Jessica Ann Reviea, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1594 Freedom Blvd Ste 100, Florence, SC 29505 Phone: 843-674-4787 | |
Jennifer Lucas Reid, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 214 W Pine St, Florence, SC 29501 Phone: 843-661-0500 Fax: 436-617-3708 | |
Christy Mcwhite, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 145 E Cheves St, Florence, SC 29506 Phone: 843-661-4835 | |
Betty Gattison, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1100 E Cheves St, Florence, SC 29506 Phone: 843-669-6694 | |
Theressa L Garris, PNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 204 E Cheves St, Florence, SC 29506 Phone: 843-777-7601 Fax: 843-662-2474 | |
Michelle D Poston, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 360 N Irby St, Florence, SC 29501 Phone: 843-667-9414 Fax: 843-667-1362 |